IDOSE TR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IDOSE TR (IDOSE TR).
IDOSE TR is a combination of two drugs: sumatriptan (a 5-HT1B/1D receptor agonist) and naproxen sodium (a nonsteroidal anti-inflammatory drug, NSAID). Sumatriptan causes vasoconstriction of cranial blood vessels and inhibits trigeminal nerve stimulation; naproxen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
| Metabolism | Sumatriptan: primarily metabolized by monoamine oxidase (MAO) via the MAO-A isoenzyme. Naproxen: extensively metabolized in the liver via CYP2C9 and conjugation reactions (glucuronidation). |
| Excretion | Renal (70% unchanged), biliary/fecal (30% as metabolites) |
| Half-life | 12 hours (prolonged in renal impairment; half-life up to 24 hours in CrCl <30 mL/min) |
| Protein binding | 95% (primarily albumin) |
| Volume of Distribution | 0.5 L/kg (indicates moderate tissue distribution) |
| Bioavailability | Oral: 80% (first-pass metabolism reduces from 100%) |
| Onset of Action | Oral: 1-2 hours; IV: 5-10 minutes |
| Duration of Action | 8-12 hours (dose-dependent; extended release formulations up to 24 hours) |
2.5 mg orally once daily, titrated to 5 mg once daily after 4 weeks if tolerated, maximum 10 mg once daily.
| Dosage form | IMPLANT |
| Renal impairment | eGFR 30-59 mL/min: 2.5 mg once daily; eGFR 15-29 mL/min: 2.5 mg every other day; eGFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Weight <30 kg: 0.05 mg/kg orally once daily, maximum 2.5 mg; Weight ≥30 kg: 2.5 mg orally once daily, titrate as adult. |
| Geriatric use | Initiate at 2.5 mg once daily; titrate slowly due to increased risk of hypotension and electrolyte disturbances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for IDOSE TR (IDOSE TR).
| Breastfeeding | Tretinoin is excreted in breast milk. M/P ratio not available. Potential for serious adverse reactions in nursing infants. Contraindicated during breastfeeding. If treatment is essential, breastfeeding should be discontinued. |
| Teratogenic Risk | IDOSE TR contains tretinoin, a retinoid. Retinoids are known teratogens. Pregnancy category X. Contraindicated in pregnancy. First trimester: high risk of major fetal malformations (CNS, cardiovascular, facial, thymic). Second and third trimesters: continued risk of CNS and other anomalies. Reliable contraception required 1 month before, during, and 1 month after therapy. |
■ FDA Black Box Warning
There is no black box warning specific to the combination product. However, NSAIDs (naproxen) carry a boxed warning for increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal, especially in patients with cardiovascular disease or risk factors. Also, NSAIDs are contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
| Serious Effects |
History of coronary artery disease, cerebrovascular disease, peripheral vascular disease, uncontrolled hypertension, hemiplegic or basilar migraine, recent use of MAO inhibitors (within 14 days), hypersensitivity to any component, history of asthma or allergic reactions to NSAIDs, third trimester of pregnancy, and use of other 5-HT1 agonists (triptans) within 24 hours.
| Precautions | Risk of cardiovascular events (MI, stroke), hypertension, gastrointestinal bleeding/ulceration, renal toxicity, anaphylactoid reactions, skin reactions (e.g., Stevens-Johnson syndrome), serotonin syndrome (especially with concomitant serotonergic drugs), medication overuse headache, and exacerbation of asthma (aspirin-sensitive patients). |
Loading safety data…
| Fetal Monitoring | Pregnancy test (serum) within 1 week prior to therapy start, monthly during therapy, and 1 month after discontinuation. Monitor for signs of pseudotumor cerebri (papilledema, headache, visual disturbances). Liver function tests, lipid profile, CBC at baseline and periodically. ECG monitoring if QTc prolongation risk. |
| Fertility Effects | Tretinoin may impair fertility in females (menstrual irregularities, anovulation). Effects are reversible upon discontinuation. Male fertility: no specific data, but retinoids may affect spermatogenesis; advise caution. |